Announcements Trials
Browse Landscape

Status

Recruiting 4Active not recruiting 3Completed 2Withdrawn 1Terminated 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

balstilimab 23-Iodobenzylguanidine 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1talazoparib 1selinexor 1ruxolitinib 1ribociclib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1idecabtagene vicleucel 1fluorodopa F 18 1fluorocholine 1dodecyl maltoside 1carbon-11 methionine 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1asciminib 1Sunitinib 1Proton Pump Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Methionine 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × lifileucel × 1 year × Clear all
NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡